1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material Levonorgestrel and Ethinyl Estradiol Tablets USP
0.1 mg/0.02 mg
Manufacturer Lupin Limited
Pithampur (M.P.) - 454 775
INDIA
Distributor Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients CAS
Levonorgestrel 797-63-7
Ethinyl Estradiol 57-63-6

3. HAZARD IDENTIFICATION

Fire and Explosion Expected to be non-combustible
Health Combination oral contraceptives should not be used in women with any of the following conditions:

- Thrombophlebitis or thromboembolic disorders
- A history of deep-vein thrombophlebitis or thromboembolic disorders
- Cerebrovascular or coronary artery disease (current or past history)
- Valvular heart disease with thrombogenic complications
- Thrombogenic rhythm disorders
- Hereditary or acquired thrombophilias
- Major surgery with prolonged immobilization
- Diabetes with vascular involvement
4. FIRST AID MEASURE

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

Overdosage
Symptoms of oral contraceptive overdosage in adults and children may include nausea, vomiting, and drowsiness/fatigue; withdrawal bleeding may occur in females. There is no specific antidote and further treatment of overdose, if necessary, is directed to the symptoms.
5. FIRE FIGHTING MEASURE

Fire and Explosion Hazards  Assume that this product is capable of sustaining combustion.

Extinguishing Media  Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures  For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products  Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions  Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions  For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods  Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling  No special control measures required for the normal handling of this product.

Storage  Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form

Levonorgestrel and ethinyl estradiol tablets USP, 0.1 mg and 0.02 mg are available in 3 wallets, each containing 28 tablets as follows.

Each wallet contains 21 white to off white round bevel edged tablets of 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, debossed with “LU” on one side and “T21” on the other side and 7 orange round bevel edged inert tablets debossed with “LU” on one side and “T22” on the other side.

They are supplied as follows:
Levonorgestrel and ethinyl estradiol tablets USP, 0.1 mg and 0.02 mg are available in a wallet (NDC 68180-854-11) of 28 tablets, such 3 wallets are packed in a carton (NDC 68180-854-13).

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinoma of The Reproductive Organs and Breasts

Numerous epidemiological studies have examined the association between the use of oral contraceptives and the incidence of breast and cervical cancer.

The risk of having breast cancer diagnosed may be slightly increased among current and recent users of combination oral contraceptives. However, this excess risk appears to decrease over time after combination oral contraceptive discontinuation and by 10 years after cessation the increased risk disappears. Some studies report an increased risk with duration of use while other studies do not and no consistent relationships have been found with dose or type of steroid. Some studies have reported a small increase in risk for women who first use combination oral contraceptives at a younger age. Most studies show a similar pattern of risk with combination oral contraceptive use regardless of a woman’s reproductive history or her family breast cancer history.

Breast cancers diagnosed in current or previous OC users tend to be less clinically advanced than in nonusers.

Women with known or suspected carcinoma of the breast or personal history of breast cancer should not use oral contraceptives because breast cancer is usually a hormonally-sensitive tumor.
Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia or invasive cervical cancer in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

In spite of many studies of the relationship between combination oral contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been established.

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

IATA/ICAO - Not Regulated
IATA Proper shipping Name    : N/A
IATA UN/ID No                : N/A
IATA Hazard Class           : N/A
IATA Packaging Group        : N/A
IATA Label                  : N/A

IMDG - Not Regulated
IMDG Proper shipping Name   : N/A
IMDG UN/ID No               : N/A
IMDG Hazard Class           : N/A
IMDG Flash Point            : N/A
IMDG Label                  : N/A

DOT - Not Regulated
DOT Proper shipping Name    : N/A
DOT UN/ID No                : N/A
DOT Hazard Class            : N/A
DOT Flash Point             : N/A
DOT Packing Group           : N/A
DOT Label                   : N/A
15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.